Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection

Table 5 Sensitivity analysis in the propensity-matched chronic kidney disease patients (n = 14580) n (%)

Model 1: CKD patients without diabetes at baseline (n =10782)
	Uninfected cohort ( = 8615)	Untreated cohort (n = 2167)
No. of ESRD	222 (2.58)	118 (5.45)
Adjusted HR (95%CI)1	1.00 (reference)	1.82 (1.45-2.28)
Model 2: CKD patients without cirrhosis at baseline (n = 13969)
	Uninfected cohort (n = 11192)	Untreated cohort (n = 2777)
No. of ESRD	401 (3.58)	191 (6.88)
Adjusted HR (95%CI)1	1.00 (reference)	1.67 (1.40-1.99)
Model 3: CKD patients without diabetes and cirrhosis at baseline (n = 10420)
	Uninfected cohort (n = 8327)	Untreated cohort (n = 2093)
No. of ESRD	218 (2.62)	116 (5.54)
Adjusted HR (95%CI)1	1.00 (reference)	1.81 (1.44-2.27)

¹Adjusted for all covariates (age per year, sex, comorbidities, urbanization level, enrolee category, number of medical visits, Charlson comorbidity index score, and propensity score) and competing mortality. ESRD: End-stage renal disease; CKD: Chronic kidney disease.